Albumin and α1-acid glycoprotein: Old acquaintances

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 8, 2013, Pages 943-954

  Filip, Zemek ^a   Jan, Korabecny ^a,b   Vendula, Sepsova ^a   Jana, Karasova Zdarova ^a,b   Kamil, Musilek ^b   Kamil, Kuca ^a,b,c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

Author keywords

1 acid glycoprotein; Drug plasma protein interactions; Equilibrium dialysis; High performance affinity chromatography; Human serum albumin; Ultracentrifugation; Ultrafiltration

Indexed keywords

DIGOXIN; FUROSEMIDE; HUMAN SERUM ALBUMIN; LITHIUM; OROSOMUCOID; SALICYLIC ACID; VALPROIC ACID; WARFARIN;

ABSORPTION SPECTROSCOPY; BINDING SITE; CLINICAL PRACTICE; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; TRANSIENT ABSORPTION SPECTROSCOPY; ULTRACENTRIFUGATION; ULTRAFILTRATION;

BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL ISCHEMIA; OROSOMUCOID; PROTEIN BINDING; SERUM ALBUMIN;

EID: 84880371653     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.790364     Document Type: Review

References (95)

1. Peters T, Anfinsen CB. Net production of serum albumin by liver slices. J Biol Chem 1950;186:805-13
2. Watanabe H, Tanase S, Nakajou K, et al. Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem J 2000;349:813-19
3. Means GE, Bender ML. Acetylation of human serum albumin by p-nitrophenyl acetate. Biochemistry 1975;14:4989-94
4. Means GE, Wu HL. The reactive tyrosine residue of human serum albumin: Characterization of its reaction with diisopropylfluorophosphate. Arch Biochem Biophys 1979;194:526-30
5. Ishima Y, Akaike T, Kragh-Hansen U, et al. S-Nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding. J Biol Chem 2008;283:34966-75
6. Peters T. All about albumin; biochemistry, genetics and medical applications. Academic Press; San Diego, CA: 1996
7. Oettl K, Satuber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007;151:580-90
8. Curry S. Lessons from the crystallographic analysis of the small molecule binding to human serum albumin. Drug Metab Pharmacokinet 2009;24:342-57
9. Kragh-Hansen U, Chuang VTG, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25:695-704
10. Quinlan GJ, Margarson MP, Mumby S, et al. Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion. Clin Sci (Lond) 1998;95:459-65
11. Sogami M, Nagoka S, Era S, et al. Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984;24:96-103
12. Hughes WL, Dintzis HM. Crystallization of the mercury dimmers of human and bovine mercaptalbumin. J Biol Chem 1964;239:845-9
13. Hayashi T, Era S, Kawai K, et al. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology 2000;6:237-43
14. Sudlow G, Birkett DJ, Wade DN. The Characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975;11:824-32
15. Hage DS, Austin J. High-performance affinity chromatography and immobilized serum albumin as probes for drug- and hormone-binding. J Chromatogr B Biomed Sci Appl 2000;739:39-54
16. Kim HS, Wainer IW. Rapid analysis of the interactions between drugs and human serum albumin (HSA) using high-performance affinity chromatography (HPAC). J Chromatogr B Biomed Sci Appl 2008;870:22-6
17. Kragh-Hansen U. Relations between high-affinity binding sites for L-tryptophan, diazepam, salicylate and Phenol Red on human serum albumin. Biochem J 1983;209:135-42
18. Kragh-Hansen U. Relations between high-affinity binding sites of markers for binding regions on human serum albumin. Biochem J 1985;225:629-38
19. Kragh-Hansen U. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol Pharmacol 1988;34:160-71
20. Joseph KS, Moser AC, Basiaga SBG, et al. Evaluation of alternatives to warfarin as probes for Sudlow site I of human serum albumin: Characterization by high-performance affinity chromatography. J Chromatogr A 2009;1216:3492-500
21. Petersen CE, Ha CE, Harohalli K, et al. A Dynamic model for bilirubin binding to human serum albumin. J Biol Chem 2000;275:20985-95
22. Varshney A, Sen P, Ahmad E, et al. Ligand binding strategies of human serum albumin: How can the cargo be utilized? Chirality 2010;22:77-87
23. Ghuman J, Zunszain PA, Peptitpas I, et al. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353:38-52
24. Varshney A, Ahmad B, Khan RH. Comparative studies of unfolding and binding of ligands to human serum albumin in the presence of fatty acid: Spectroscopic approach. Int J Biol Macromol 2008;42:483-90
25. Dill KA, Shortie D. Denatured states of proteins. Ann Rev Biochem 1991;60:795-825
26. Petitpas I, Petersen CE, Ha CE, et al. Structural basis of albumin-thyroxine interactions and familial dysalbuminemichyperthyroxinemia. Proc Natl Acad Sci USA 2003;100:6440-5
27. Sugio S, Kashima AS, Mochizuki S, et al. Crystal structure of human serum albumin at 2.5 A ° resolution. Protein Eng 1999;12:439-46
28. Petitpas I, Grune T, Bhattacharya AA, Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 2001;314:955-60
29. Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev 2003;23:275-301
30. Colmenarejo G, Alvarez-Pedraglio A, Lavander JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 2001;44:4370-8
31. Kratochvil NA, Huber W, Muller F, et al. Predicting plasma protein binding of drugs: A new approach. Biochem Pharmacol 2002;64:1355-74
32. Saiakhov RD, Stefan LR, Klopman G. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspect Drug Discov Des 2000;19:133-55
33. Deeb O, Hemmateenejad B. ANN-QSAR model of drug-binding to human serum albumin. Chem Biol Drug Design 2007;70:19-29
34. Ghuman J, Zunszain PA, Petitpas I, et al. Structural basis of the drug-binding specifity of human serum albumin. J Mol Biol 2005;353:38-52
35. Sueyasu M, Fujito K, Shuto H, et al. Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg 2000;91:736-40
36. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 1981;33:17-53
37. Takamura N, Shinozawa S, Maruyama T, et al. Effects of fatty acids on serum binding between furosemide and valproic acid. Biol Pharm Bull 1998;21:174-6
38. Takamura N, Maruyama T, Otagiri M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. Clin Chem 1997;43:2274-80
39. Ger J van der Vusse. Albumin as fatty acid transporter. Drug Metab Pharmacokinet 2009;24:300-7
40. Yu HY, Shen YZ. Displacement effect of valproate on bilirubin-albumin binding in human plasma. J Formos Med Assoc 1999;98:201-4
41. Maruyama K, Harada S, Nishigori H, Iwatsuru M. Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin. Chem Pharm Bull 1984;32:2414-20
42. Brodersen R, Robertson A. Ceftriaxone binding to human serum albumin: Competition with bilirubin. Mol Pharmacol 1989;36:478-83
43. Gaze DC. Ischemia modified albumin: A novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009;24:333-41
44. Apple FS, Quist HE, Otto AP, et al. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002;48:1097-100
45. Marx G, Chevion M. Site-specific modification of albumin by free radicals. Reaction with copper(II) and ascorbate. Biochem J 1986;236:397-400
46. Mothes E, Faller P. Evidence that the principal CoII-binding site in human serum albumin is not at the N-terminus: Implication on the albumin cobalt binding tests for detecting myocardial ischemia. Biochemistry 2007;46:2267-74
47. Otagari M, Kragh-Hansen U, Imai T. Albumins with new functions and clinical applications. Drug Metab Pharmacokinet 2009;24:285-6
48. Allen PC, Hill EA, Stokes AM. Alpha 1-acid glycoprotein in plasma proteins: Analytical and preparative techniques. Blackwell Scientific; Oxford (UK): 1977. p. 207-9
49. Kremer JM, Wilting J, Jansen LH. Drug binding to human alpha 1-acid glycoprotein in health and disease. Pharmacol Rev 1988;40:1-47
50. Ganguly M, Carnigham RH, Westphal U. Steroid-protein interactions. XIV. Interaction between human alpha 1-acid glycoprotein and progesterone. Biochemistry 1967;6:2803-14
51. Fitos I, Visy J, Zsila F, et al. Specific ligand binding on genetic variants of human alpha 1-acid glycoprotein studied by circular dichroism spectroscopy. Biochem Pharmacol 2004;67:679-88
52. Yuasa I, Umetsu K, Vogt U, et al. Human orosomucoid polymorphism: Molecular basis of the three common ORM1 allels, ORM1&z.ast;F1, ORM1&z.ast;F2 and ORM1&z.ast;S. Hum Genet 1997;99:393-408
53. Yuasa I, Weidinger S, Umetsu K, et al. Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature. Vox Sang 1993;64:47-55
54. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, 1-methadone, and d1-methadone to proteins in plasma of healthy volunteers: Role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-46
55. Baumann P, Eap CB. Contribution of the variants of alpha 1-acid glycoprotein to its binding of drugs. Prog Clin Biol Res 1989;300:379-97
56. Jolliet-Riant P, Boukef MF, Duche JC, et al. The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci 1998;62:L219-26
57. Hanada K, Ohta T, Hirai M, et al. Enantio-selective binding of propranolol, disopyramide, and verapamil to human alpha 1-acid glycoprotein. J Pharm Sci 2000;89:751-7
58. Bree F, Eap CB, Baumann P, et al. Comparison of drug binding capacities of two AAG peptidic variants of human origin. Prog clin Biol Res 1989;300:399-403
59. Herve F, Gomas E, Duche JC, Tillement JP. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Phramcol 1993;36:241-9
60. Herve F, Duche JC, d'Athis P, et al. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: Evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 1996;6:403-15
61. Eap CB, Cuendet C, Baumann P. Selectivity in the binding of psychotropic drugs to the variants of alpha 1-acid glycoprotein. Naunyn Schmiedebregs Arch Pharmacol 1988;337:220-4
62. Eap CB, Cuendet C, Baumann P. Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J Pharm Pharmacol 1988;40:767-70
63. Schonfeld DL, Ravelli RBG, Mueller U, Skerra A. The 1.8-A° crystal structure of a1-acid glycoprotein (orosomucoid)solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J Mol Biol 2008;384:393-405
64. Colombo S, Buclin T, Décostered LA, et al. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Therapeutic 2006;80:307-18
65. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and Tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:2091-6
66. Barrail-Tran A, Mentré F, Cosson C, et al. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother 2010;54:614-19
67. Ofotokun I, Lennox JL, Eaton ME, et al. Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposure. J Clin Pharmacol 2011; Epub ahead of print
68. Bachtiar I, Kheng V, Wibowo GA, et al. Alpha 1-acid glycoprotein as potential biomarker for alpha- fetoprotein-low hepatocellular carcinoma. BMC Research Notes 2010;3:319
69. Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 2003;92:967-74
70. Sebille B, Zini R, Madjar CV, et al. Separation procedures used to reveal and follow drug-protein binding. J Chromatogr 1990;531:51-77
71. Vuignier K, Schappler J, Veuthy JL, et al. Drug-Protein binding: A critical review of analytical tools. Anal Bioanal Chem 2010;398:53-66
72. Hage DS. Chromatographic and electrophoretic studies of protein binding to chiral solutes. J Chromatogr A 2001;906:459-81
73. Kragh-Hansen U, Dorge E, Pedersen AO. Rate of dialysis technique: Theoretical and practical aspects. Anal Biochem 2005;340:145-53
74. Waters NJ, Jones R, Willimas G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 2008;97:4586-95
75. Kariv I, Cao H, Oldemburg KR. Development of a high throughput equilibrium dialysis method. J Pharm Sci 2001;90:580-7
76. Xie Y, Zhang D, Ben-Amotz D. Protein-ligand binding detected using ultrafiltration Raman difference spectroscopy. Anal Biochem 2008;373:154-60
77. Su S, Yu Y, Zhang Y, et al. A development of LC-MS method combining ultrafiltration and lyophilization for determination of r-RGD-Hirudin in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2008;870:27-31
78. Harding SE, Rowe AJ. Insight into protein-protein interactions from analytical ultracentrifugation. Biochem Soc Trans 2010;38:901-7
79. Planken KL, Colfen H. Analytical ultracentrifugation of colloids. Nanoscale 2010;2:1849-69
80. Rich RL, Demeler B, Ashby K, et al. Domain structure of the Staphylococcus aureus collagen adhesion. Biochemistry 1998;37:15423-33
81. Fletcher TM, Serwer P, Hansen JC. Quantitative analysis of macromolecular conformational changes using agarose gel electrophoresis: Application to chromatin folding. Biochemistry 1994;33:10859-63
82. Schwarz PM, Felthauser A, Fletcher TM, Hansen JC. Reversible oligonucleosome self-association: Dependence on divalent cations and core histone tail domains. Biochemistry 1996;35:4009-15
83. Rippe K, Mücke N, Schulz A. Association states of the transcription activator protein NtrC from E. coli determined by analytical ultracentrifugation. J Mol Biol 1998;278:915-33
84. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998;53:908-15
85. Cole JL, Carroll SS, Blue ES, et al. Activation of RNase L by 2',5'-oligoadenylates. Biophysical characterization. J Biol Chem 1997;272:19187-92
86. Kim HS, Wainer WI. Rapid analysis of the interactions between drugs and human serum albumin (HSA) using high-performance affinity chromatography (HPAC). J Chromatogr B Analyt Technol Biomed Life Sci 2008;870:22-6
87. Nelson MA, Reiter WS, Hage DS. Chromatographic competitive binding immunoassays: A comparison of the sequential and simultaneous injection methods. Biomed Chromatogr 2003;17:188-200
88. Kim HS, Hage DS. Chromatographic analysis of carbamazepine binding to human serum albumin. J Chromatogr B 2005;816:57-66
89. Hage DS. High-performance affinity chromatography: A powerful tool for studying serum protein binding. J Chromatogr B 2002;768:3-30
90. Jospeh KS, Hage DS. Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B 2010;878:1590-8
91. Tweed SA. Effects of heterogeneity on the characterization of chromatographic stationary phases. PhD Thesis Lincoln January; University of Nebraska: 1997
92. Surapaneni R, Rohini P, Vobbilireddi SK, Mounika G. Ultrafast spectroscopy: A review. Int J Pharm 2012;2:187-94
93. Martin C, Gil M, Cohen B, Douhal A. Ultrafast photodynamics of drugs in nanocavities: Cyclodextrins and human serum albumin protein. Langmuir 2012;28:6746-59
94. Nuernberger P, Lee KF, Bonvalet A, et al. Strong ligand-protein interactions revealed by ultrafast infrared spectroscopy of CO in the heme pocket of the oxygen sensor FixL. J Am Chem Soc 2011;133:17110-13
95. Schonfeld DL, Ravelli RB, Mueller U, Skerra A. The 1.8 A ° crystal structure of alpha 1-acid glycoprotein (orosomucoid)solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J Mol Biol 2008;384:393-405